46. If a medication presents a serious safety concern, the FDA may require the manufacturer to implement a
Answer: D
A REMS program may be required by the FDA for medications with serious safety concerns.
A REMS (Risk Evaluation and Mitigation Strategy) program is specifically designed to ensure that the benefits of a medication outweigh its risks. When a medication presents serious safety concerns, the FDA mandates such programs to safeguard public health.
A) MedWatch report.
A MedWatch report is a tool for healthcare professionals and the public to report adverse events and product problems, but it does not serve as a proactive safety measure like a REMS program. While it is important for monitoring safety, it does not impose any specific requirements on manufacturers.
B) Failure modes and effects analysis.
Failure modes and effects analysis (FMEA) is a systematic approach to identifying potential failure points in a process, but it is generally used within the context of product development and quality assurance rather than as an FDA requirement for medications with safety concerns. Therefore, it is not applicable in this case.
C) Root-cause analysis.
Root-cause analysis is a method used to identify the fundamental cause of a problem, often after an incident has occurred. While it can be beneficial in understanding safety issues, it is not a requirement imposed by the FDA for medications with serious safety concerns like a REMS program is.
D) REMS program.
A REMS program is a regulatory requirement that can be enforced by the FDA when a medication poses significant safety risks. This program ensures that the risks are communicated effectively and that the necessary steps are taken to mitigate those risks, making it the correct choice in this context.
Conclusion
The REMS program is the definitive answer as it directly addresses the need for risk management in medications that pose serious safety issues. The other options, while relevant to safety and risk management in different contexts, do not fulfill the specific regulatory requirements set by the FDA for high-risk medications. Hence, they are not suitable alternatives to a REMS program.